MedTrace Logo

Study of How Safe and Effective Tarlatamab is in Brain Cancers

NCT06776250 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-09-19

No results posted yet for this study

Summary

This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.

Conditions

  • Astrocytic Tumor
  • Oligodendroglial Tumor

Interventions

DRUG

Tarlatamab

Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Eric Chen, MD · Princess Margaret Cancer Centre/University Health Network

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-18
Primary Completion
2028-03-03
Completion
2028-03-03

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06776250 on ClinicalTrials.gov